Eli Lilly's Orforglipron Shows Promise in Weight Maintenance
In a groundbreaking Phase 3 trial known as ATTAIN-MAINTAIN, Eli Lilly and Company announced that orforglipron successfully met its primary and all key secondary endpoints concerning weight maintenance compared to a placebo. This trial followed a previous treatment phase using injectable therapies such as Wegovy or Zepbound.
Key Findings from ATTAIN-MAINTAIN Trial
The participants who transitioned to orforglipron after using Wegovy were able to maintain all but 0.9 kg of their considerable weight loss. The drug, which is an oral glucagon-like peptide-1 (GLP-1) receptor agonist, provides a new, convenient option for those aiming to keep their weight in check.
Dr. Kenneth Custer, the executive vice president at Lilly Cardiometabolic Health, emphasized the challenge many face in sustaining weight loss. He noted that the results from the ATTAIN-MAINTAIN trial highlight how orforglipron can support individuals in maintaining their weight post-initial weight loss efforts.
Details of the Trial
The ATTAIN-MAINTAIN trial involved participants who completed the SURMOUNT-5 trial and subsequently transitioned to either orforglipron or a placebo. Over the course of 52 weeks, the data suggested that those who moved to orforglipron from Wegovy managed to preserve a significant percentage of their earlier weight loss, maintaining a difference of 0.9 kg compared to the placebo group. Furthermore, participants switching from Zepbound enjoyed an even greater maintenance benefit, averaging a difference of 5.0 kg.
Study Results at 24 Weeks
At the 24-week mark, before the placebo participants could receive orforglipron as a recovery option, those previously on Wegovy recorded a slight weight change of -0.1 kg against a 9.4 kg loss for those on the placebo. In contrast, participants transitioning from Zepbound saw a change of 2.6 kg compared to 9.1 kg in the placebo group.
Safety Profile of Orforglipron
The overall safety profile of orforglipron based on the ATTAIN-MAINTAIN trial was consistent with findings from prior studies, showcasing a pattern of mild to moderate gastrointestinal-related side effects. The discontinuation rates due to adverse events were manageable, with 4.8% for orforglipron and 7.2% for those receiving Zepbound. Importantly, the analysis showed that no significant hepatic safety issues were flagged.
Future Outlook for Orforglipron
As part of its development, Lilly has submitted a new drug application to the U.S. Food and Drug Administration for orforglipron's use in obesity treatment. The company previously received a Commissioner's National Priority Voucher from the FDA, further emphasizing the priority and potential impact of orforglipron in transforming obesity management.
What is Orforglipron?
Orforglipron is a daily oral medication that acts as a GLP-1 receptor agonist. Its formulation allows for consumption at any time without dietary restrictions. Following its discovery by Chugai Pharmaceutical Co., Ltd. and subsequent licensing by Lilly in 2018, orforglipron is currently in several Phase 3 studies targeting not only obesity management but also possible applications for type 2 diabetes and other weight-related conditions.
Understanding the ATTAIN Clinical Trial Program
The ATTAIN-MAINTAIN trial, itself part of a broader ATTAIN clinical program, focused on participants with a history of obesity or overweight who previously experienced weight loss in the SURMOUNT-5 trial. In total, 376 participants took part, randomized against a placebo to evaluate the effectiveness of once-daily orforglipron compared to existing injectable therapies.
Conclusion
The promising results from the ATTAIN-MAINTAIN trial highlight Eli Lilly's continued commitment to addressing obesity through innovative therapies. As more individuals struggle with weight management, orforglipron may emerge as a crucial tool in helping maintain healthy body weight after significant weight loss.
Frequently Asked Questions
What is the ATTAIN-MAINTAIN trial about?
The ATTAIN-MAINTAIN trial evaluated the effectiveness of orforglipron in maintaining weight loss after patients switched from injectable medications like Wegovy or Zepbound.
How effective is orforglipron in weight maintenance?
Participants transitioning to orforglipron maintained an average weight close to their initial loss, with a slight gain of only 0.9 kg compared to placebo.
What are the common side effects of orforglipron?
The most frequent side effects were gastrointestinal issues that ranged in severity from mild to moderate.
What regulatory steps has Lilly taken with orforglipron?
Lilly has submitted an application for orforglipron's approval to the FDA for its potential treatment of obesity.
What does the future hold for orforglipron?
Detailed results will be shared in future medical meetings, with further studies planned to expand usage beyond obesity management.
